Journal
LANCET DIABETES & ENDOCRINOLOGY
Volume 6, Issue 1, Pages 69-80Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S2213-8587(17)30186-9
Keywords
-
Categories
Funding
- Merck, Sharpe Dohme
- Novartis
- Boehringer Ingelheim
- Janssen
- AstraZeneca
- Novo Nordisk
- Eli Lilly
- Sanofi-Aventis
- Elcelyx
- Lexicon
- Poxel
- Binding Site
Ask authors/readers for more resources
The prevalence of type 2 diabetes in adolescents and young adults is dramatically increasing. Similar to older-onset type 2 diabetes, the major predisposing risk factors are obesity, family history, and sedentary lifestyle. Onset of diabetes at a younger age (defined here as up to age 40 years) is associated with longer disease exposure and increased risk for chronic complications. Young-onset type 2 diabetes also affects more individuals of working age, accentuating the adverse societal effects of the disease. Furthermore, evidence is accumulating that young-onset type 2 diabetes has a more aggressive disease phenotype, leading to premature development of complications, with adverse effects on quality of life and unfavourable effects on long-term outcomes, raising the possibility of a future public health catastrophe. In this Review, we describe the epidemiology and existing knowledge regarding pathophysiology, risk factors, complications, and management of type 2 diabetes in adolescents and young adults.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available